Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan

NCT01424319 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Diabetic Nephropathy

Interventions

DRUG: Atrasentan low dose group
DRUG: Atrasentan high dose group
DRUG: Atrasentan placebo group

Sponsor

AbbVie (prior sponsor, Abbott)